Cancer nanomedicines for enhanced immunotherapy

Jong Hoon Ha; Wen Jiang; Kristin Huntoon; Dae Yong Lee; Betty Y.S. Kim

doi:10.1016/B978-0-12-822425-0.00075-0

Cancer nanomedicines for enhanced immunotherapy

Jong Hoon Ha, Wen Jiang, Kristin Huntoon, Dae Yong Lee, Betty Y.S. Kim

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Incorporating nanotechnology into cancer immunotherapy has provided numerous therapeutic approaches that can surpass conventional immunotherapy. Nanoparticles are promising delivery carriers that enable targeted delivery of cargo molecules to enhance therapeutic efficacy while preventing adverse effects. This article highlights how nanomaterials can reinforce immunotherapy-mediated antitumor immunity by combatting current immunotherapeutic challenges. We will also discuss a variety of cancer nanomedicine-assisted immunotherapies based on immunogenic cell death (ICD) induction, vaccination, and direct activation of innate and adaptive immune cells.

Original language	English (US)
Title of host publication	Encyclopedia of Nanomaterials
Publisher	Elsevier
Pages	V3-657-V3-672
ISBN (Electronic)	9780128224236
DOIs	https://doi.org/10.1016/B978-0-12-822425-0.00075-0
State	Published - Jan 1 2023

Keywords

Adoptive cell therapy
Cancer cell membrane vaccine
Cancer immunotherapy
Cancer nanomedicine
Cancer nanovaccine
Gene vaccine
Immunogenic cell death
Innate immunity activation
Nanoparticle-mediated delivery
NK cell activation
Peptide vaccine
Phagocytosis
Tumor-associated macrophage

ASJC Scopus subject areas

General Chemistry

Access to Document

10.1016/B978-0-12-822425-0.00075-0

Cite this

@inbook{d19c6a6e6ffd40e48eab80e1840eb6b3,

title = "Cancer nanomedicines for enhanced immunotherapy",

abstract = "Incorporating nanotechnology into cancer immunotherapy has provided numerous therapeutic approaches that can surpass conventional immunotherapy. Nanoparticles are promising delivery carriers that enable targeted delivery of cargo molecules to enhance therapeutic efficacy while preventing adverse effects. This article highlights how nanomaterials can reinforce immunotherapy-mediated antitumor immunity by combatting current immunotherapeutic challenges. We will also discuss a variety of cancer nanomedicine-assisted immunotherapies based on immunogenic cell death (ICD) induction, vaccination, and direct activation of innate and adaptive immune cells.",

keywords = "Adoptive cell therapy, Cancer cell membrane vaccine, Cancer immunotherapy, Cancer nanomedicine, Cancer nanovaccine, Gene vaccine, Immunogenic cell death, Innate immunity activation, Nanoparticle-mediated delivery, NK cell activation, Peptide vaccine, Phagocytosis, Tumor-associated macrophage",

author = "Ha, {Jong Hoon} and Wen Jiang and Kristin Huntoon and Lee, {Dae Yong} and Kim, {Betty Y.S.}",

year = "2023",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-822425-0.00075-0",

language = "English (US)",

pages = "V3--657--V3--672",

booktitle = "Encyclopedia of Nanomaterials",

publisher = "Elsevier",

}

TY - CHAP

T1 - Cancer nanomedicines for enhanced immunotherapy

AU - Ha, Jong Hoon

AU - Jiang, Wen

AU - Huntoon, Kristin

AU - Lee, Dae Yong

AU - Kim, Betty Y.S.

PY - 2023/1/1

Y1 - 2023/1/1

N2 - Incorporating nanotechnology into cancer immunotherapy has provided numerous therapeutic approaches that can surpass conventional immunotherapy. Nanoparticles are promising delivery carriers that enable targeted delivery of cargo molecules to enhance therapeutic efficacy while preventing adverse effects. This article highlights how nanomaterials can reinforce immunotherapy-mediated antitumor immunity by combatting current immunotherapeutic challenges. We will also discuss a variety of cancer nanomedicine-assisted immunotherapies based on immunogenic cell death (ICD) induction, vaccination, and direct activation of innate and adaptive immune cells.

AB - Incorporating nanotechnology into cancer immunotherapy has provided numerous therapeutic approaches that can surpass conventional immunotherapy. Nanoparticles are promising delivery carriers that enable targeted delivery of cargo molecules to enhance therapeutic efficacy while preventing adverse effects. This article highlights how nanomaterials can reinforce immunotherapy-mediated antitumor immunity by combatting current immunotherapeutic challenges. We will also discuss a variety of cancer nanomedicine-assisted immunotherapies based on immunogenic cell death (ICD) induction, vaccination, and direct activation of innate and adaptive immune cells.

KW - Adoptive cell therapy

KW - Cancer cell membrane vaccine

KW - Cancer immunotherapy

KW - Cancer nanomedicine

KW - Cancer nanovaccine

KW - Gene vaccine

KW - Immunogenic cell death

KW - Innate immunity activation

KW - Nanoparticle-mediated delivery

KW - NK cell activation

KW - Peptide vaccine

KW - Phagocytosis

KW - Tumor-associated macrophage

UR - http://www.scopus.com/inward/record.url?scp=85171019192&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85171019192&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-822425-0.00075-0

DO - 10.1016/B978-0-12-822425-0.00075-0

M3 - Chapter

AN - SCOPUS:85171019192

SP - V3-657-V3-672

BT - Encyclopedia of Nanomaterials

PB - Elsevier

ER -

Cancer nanomedicines for enhanced immunotherapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this